Effectiveness of topically applied halofuginone in management of subglottic stenosis in rats

• Published in: Otolaryngology-head and neck surgery Vol. 140; no. 5; pp. 720 - 723
• Main Authors: Ertuğrul, Eylem Ertug, Çekin, İ. Engin, Cincik, Hakan, Doğru, Salim, Güngör, Atila
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA Mosby, Inc 01-05-2009; SAGE Publications
• Subjects: Administration, Topical; Animals; Fibrosis - drug therapy; Fibrosis - pathology; Laryngostenosis - drug therapy; Laryngostenosis - pathology; Piperidines - administration & dosage; Piperidines - pharmacology; Protein Synthesis Inhibitors - administration & dosage; Protein Synthesis Inhibitors - pharmacology; Quinazolinones - administration & dosage; Quinazolinones - pharmacology; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric
• ISSN: 0194-5998; 1097-6817
• DOI: 10.1016/j.otohns.2008.12.050

The aim of the study is to ascertain the antifibrotic effect of topically applied halofuginone after acute subglottic injury.
After standardized trauma to subglottic area, rats were divided into two groups: the study group that received treatment and the control group that did not. The subjects were treated with topical application of cottonoid soaked in 30 mg/dL halofuginone solution for 5 minutes after subglottic trauma. The larynx specimens were examined histopathologically by light microscopy to assess fibrosis, epithelialization, inflammation, and necrosis.
The fibrosis indexes of the treated group were significantly less than those of the control group (
P < 0.05).
Topically applied halofuginone hydrobromide decreases fibrosis/scar tissue formation secondary to experimentally induced acute subglottic trauma.